Drug intelligence / Profile preview

NVR 3-778 + peginterferon alfa-2a

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

NVR 3-778 + peginterferon alfa-2a is a combination therapy composed of NVR 3-778, a small-molecule hepatitis B virus (HBV) capsid assembly modulator, and peginterferon alfa-2a, a pegylated recombinant human interferon used as an immunomodulatory and antiviral agent. NVR 3-778 inhibits HBV replication by targeting and modulating the core protein, interfering with viral capsid assembly and blocking pregenomic RNA encapsidation and subsequent production of infectious HBV DNA and RNA particles. Peginterferon alfa-2a activates human type I interferon receptors, leading to JAK/STAT pathway signaling and induction of innate antiviral gene expression. The combination has been explored in clinical contexts for the treatment of chronic hepatitis B, aiming to provide additive or synergistic antiviral effects by targeting different stages of the HBV life cycle[1][2][3][5].

Brand names: Pegasys
Other names: peginterferon alfa-2a

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)HBc (Hepatitis B virus core protein)IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on NVR 3-778 + peginterferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVR 3-778 + peginterferon alfa-2a.

Explore the full profile